18
“When the going gets tough, the tough get going”
By Ram Aiyar, CEO of Korro Bio, as part of the From the Trenches feature of LifeSciVC.
It has been quite a start to the 2025 year. The sentiment around biotech starting from the yearly JPM conference has been “sour” at best – see post from Atlas’ Aimee Raleigh (here). Since then, sentiment has gotten progressively worse due to the many uncertainties that exist for investors. When you then layer on the opportunity costs for non-healthcare specialists for return-on-investment, the uncertainty around tariffs, the hushed whispering of the “R” word, the areas where Limited Partners…